Lenvatinib (Kisplyx®)

Assessment Status Rapid Review Complete
Drug Lenvatinib
Brand Kisplyx®
Indication In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Assessment Process
Rapid review commissioned 05/05/2017
Rapid review completed 18/05/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.